[Ip-health] Rwanda News Agency: Country notifies WTO of plan to import cheap, generic Aids drugs [21 July 2007]

[Richard Elliott]

This is a multi-part message in MIME format.
--
[ Picked text/plain from multipart/alternative ]


http://allafrica.com/stories/200707231394.html



Country Notifies WTO of Plan to Import Cheap, Generic Aids Drugs

Rwanda News Agency/Agence Rwandaise d'Information (Kigali)
NEWS
21 July 2007
Posted to the web 23 July 2007
Kigali

Rwanda plans to import a generic HIV/AIDS medicine made in Canada, making i=
t
the first country to test a World Trade Organization waiver on drug patents=
,
the World Trade Organisation (WTO) has reported.

In a submission to the WTO by Rwanda, according to its website, the country
said it expects over the next two years to buy 260,000 packs of TriAvir, a
fixed-dose combination of widely used anti-AIDS drugs lamivudine, zidovudin=
e
and nevirapine. The generic product is manufactured in Canada by Apotex Inc=
.


This essentially means Rwanda has invoked a never-before-used August 2003
waiver to WTO's intellectual property rules, meant to allow poor countries
with public health problems to import generics when they cannot manufacture
the drugs themselves.

When contacted about the development, National Aids Commission Executive
Secretary Dr. Agnes Binagwaho declined to talk to RNA on phone preferring a=
n
arranged interview in her office next month. She said she was at the airpor=
t
"filling in documents" for her flight.

However after persuasion, she referred RNA to the Ministers of Health. By
Press time, RNA could neither establish contact with the Minister Dr.
Ntawukuriryayo Jean Damascene nor his deputy - Dr. Nyaruhirira Innocent.

The trade body writes that Rwanda on July 19 2007 became the first country
to inform the WTO that it is using the 2003 decision designed to ease the
way for countries with public health problems to import cheaper generics.
These drugs are made under compulsory licensing elsewhere when they are
unable to manufacture the medicines themselves.

The waiver - often referred to as the "paragraph 6 system" covering
implementing paragraph 6 of the Doha trade Declaration on the TRIPS
Agreement and Public Health.

The Rwanda notification comes under paragraph 2 which requires eligible
importing countries to report the details of the medicines they intend to
import.

However, the WTO also said as a least-developed country, Rwanda does not
have to notify that it wants to be an "eligible importing member" of the
2003 decision (and 2005 amendment decision).

According to Reuters, development campaigners such as Oxfam have criticized
"the paragraph 6 solution," as the waiver is often called, as being too
burdensome because of its onerous reporting rules and because it requires
would-be exporters to negotiate with drug patent holders for the right to
sell generics abroad.

Under WTO rules, countries can issue a "compulsory license" to manufacture
generic versions of patented drugs deemed critical to public health so long
as the medicines are meant to be distributed domestically, Reuters wrote.

Thailand has over the past year issued compulsory licenses for generics for
its own market, meaning it did not need to notify the WTO as Rwanda has.
Drugmakers often reduce prices to keep countries as clients and avoid
compulsory licensing.

The WTO's 150 member states have until December to ratify a decision to mak=
e
the waiver a permanent amendment of the TRIPS (Trade Related Aspects of
Intellectual Property Rights) agreement, but until the Rwandan move, no
country had used it.

Celine Charveriat, head of Oxfam's Make Trade Fair campaign, told Reuters
that Rwanda's experience may determine the future for the WTO waiver
designed to improve access to medicines for the poor.

"We hope that Rwanda's action will lead to an increase in the number of poo=
r
people who can get antiretrovirals. If found unworkable, the provision must
be changed," she said.





_________________________________

Richard Elliott

Deputy Director

Canadian HIV/AIDS Legal Network

+1 (416) 595-1666 ext. 229



Directeur adjoint

R=E9seau juridique canadien VIH/sida

+1 (416) 595-1666 poste 229



--